Annual report
7776.TEDINET S100VGWL
Period2024-01-01 → 2024-12-31
Filed2025-03-26
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 92
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥193m | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥190m | 2023-01-01 → 2023-12-31 | Standalone | Net sales |
| Revenue | ¥126m | 2022-01-01 → 2022-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥162m | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥199m | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥846m | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Operating income | −¥698m | 2023-01-01 → 2023-12-31 | Standalone | Operating income |
| Ordinary income | −¥848m | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥710m | 2023-01-01 → 2023-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥754m | 2022-01-01 → 2022-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥887m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥866m | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥745m | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥729m | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥858m | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥846m | 2023-01-01 → 2023-12-31 | Standalone | Income before income taxes |
| Net income (owners) | −¥915m | 2021-01-01 → 2021-12-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥784m | 2020-01-01 → 2020-12-31d | Standalone | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥860m | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥847m | 2023-01-01 → 2023-12-31 | Standalone | Profit loss |
| Net income | −¥760m | 2022-01-01 → 2022-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥913m | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥768m | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.4bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2023-12-31 | Standalone | Assets |
| Total assets | ¥1.5bn | at 2022-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.4bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.4bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.8bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.8bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥270m | at 2024-12-31 | Standalone | Liabilities |
| Total liabilities | ¥301m | at 2023-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.2bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2023-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2022-12-31d | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.0bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.5bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.6bn | at 2020-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-12-31d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥931m | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.5bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥866m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥779m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥718m | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥817m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥701m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥18m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥56m | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥62m | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥110m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥13m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥855m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.8bn | 2023-01-01 → 2023-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥882m | 2022-01-01 → 2022-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥397m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-25.72 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-29.43 | 2023-01-01 → 2023-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.31 | 2022-01-01 → 2022-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-53.18 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-53.08 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-55.31 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-54.19 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥62.1 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥68.08 | at 2023-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥47.26 | at 2022-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥56.44 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥57.43 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥93.85 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥95.7 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 88.5% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.9% | at 2023-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.8% | at 2022-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.0% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.2% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 34,666,419 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 31,459,019 | at 2023-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,422,619 | at 2022-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,759,419 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,008,319 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 38 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 35 | at 2023-12-31 | Standalone | Number of employees |
| Employees | 30 | at 2022-12-31d | Standalone | Number of employees |
| Employees | 44 | at 2021-12-31d | Standalone | Number of employees |
| Employees | 40 | at 2020-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-01-01 → 2024-12-31 | ¥16m |
| Reconciling Itemsreconciling | segment assets | at 2024-12-31 | ¥2.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥230m |
| Cell Sheet Regenerative Medicinereportable segment | employees | at 2024-12-31 | 22 pure |
| Cell Sheet Regenerative Medicinereportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥1m |
| Cell Sheet Regenerative Medicinereportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥1m |
| Cell Sheet Regenerative Medicinereportable segment | segment assets | at 2024-12-31 | ¥70m |
| Cell Sheet Regenerative Medicinereportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥596m |
| Laboratory Consumables And Equipmentreportable segment | capex | 2024-01-01 → 2024-12-31 | ¥2m |
| Laboratory Consumables And Equipmentreportable segment | employees | at 2024-12-31 | 11 pure |
| Laboratory Consumables And Equipmentreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥192m |
| Laboratory Consumables And Equipmentreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥192m |
| Laboratory Consumables And Equipmentreportable segment | segment assets | at 2024-12-31 | ¥121m |
| Laboratory Consumables And Equipmentreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥21m |
| —segment total | capex | 2024-01-01 → 2024-12-31 | ¥2m |
| —segment total | revenue | 2024-01-01 → 2024-12-31 | ¥193m |
| —segment total | revenue external | 2024-01-01 → 2024-12-31 | ¥193m |
| —segment total | segment assets | at 2024-12-31 | ¥191m |
| —segment total | segment profit | 2024-01-01 → 2024-12-31 | −¥616m |
| Reconciling Itemsreconciling | capex | 2023-01-01 → 2023-12-31 | ¥21m |
| Reconciling Itemsreconciling | segment assets | at 2023-12-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-01-01 → 2023-12-31 | −¥197m |
| Cell Sheet Regenerative Medicinereportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥8m |
| Cell Sheet Regenerative Medicinereportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥8m |
| Cell Sheet Regenerative Medicinereportable segment | segment assets | at 2023-12-31 | ¥65m |
| Cell Sheet Regenerative Medicinereportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥469m |
| Laboratory Consumables And Equipmentreportable segment | capex | 2023-01-01 → 2023-12-31 | ¥770,000 |
| Laboratory Consumables And Equipmentreportable segment | depreciation | 2023-01-01 → 2023-12-31 | ¥8m |
| Laboratory Consumables And Equipmentreportable segment | revenue | 2023-01-01 → 2023-12-31 | ¥182m |
| Laboratory Consumables And Equipmentreportable segment | revenue external | 2023-01-01 → 2023-12-31 | ¥182m |
| Laboratory Consumables And Equipmentreportable segment | segment assets | at 2023-12-31 | ¥133m |
| Laboratory Consumables And Equipmentreportable segment | segment profit | 2023-01-01 → 2023-12-31 | −¥32m |
| —segment total | capex | 2023-01-01 → 2023-12-31 | ¥770,000 |
| —segment total | depreciation | 2023-01-01 → 2023-12-31 | ¥8m |
| —segment total | revenue | 2023-01-01 → 2023-12-31 | ¥190m |
| —segment total | revenue external | 2023-01-01 → 2023-12-31 | ¥190m |
| —segment total | segment assets | at 2023-12-31 | ¥198m |
| —segment total | segment profit | 2023-01-01 → 2023-12-31 | −¥501m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 991
| Item | Context | Value | Unit |
|---|---|---|---|
| Current fiscal year start date | FilingDateInstant | 2024-01-01 | |
| Current period end date | FilingDateInstant | 2024-12-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2024-12-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-01-01 | |
| Comparative period end date | FilingDateInstant | 2023-12-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-12-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Strategy (text) | FilingDateInstant | Text · Plus | |
| Policy on development of human resources and internal environment strategy (text) | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus | |
| Metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics metrics and targets (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Research and development activities (text) | FilingDateInstant | Text · Plus | |
| Overview of capital expenditures etc (text) | FilingDateInstant | Text · Plus | |
| Major facilities (text) | FilingDateInstant | Text · Plus | |
| Planned additions retirements etc of facilities (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)完全議決権株式であり権利内容に何ら限定のない当社における標準となる株式であり、単元株式は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Description of rights plan (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Shareholding by shareholder category (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)楽天証券株式会社 | |
| Address major shareholders | CurrentYearInstant_No1MajorShareholdersMember | Original text (Japanese)東京都港区南青山２丁目６番２１号 | |
| Name major shareholders | CurrentYearInstant_No2MajorShareholdersMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |